Clinical Development of Siltuximab

Current Oncology Reports

Volumn 17, Issue 7, 2015, Pages

  Davis, Christine C ^a   Shah, Katherine S ^a   Lechowicz, Mary Jo ^b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Interleukin 6; Monoclonal antibody; Multicentric Castleman s disease; Myeloma; Siltuximab

Indexed keywords

SILTUXIMAB; ANTINEOPLASTIC AGENT; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CELLULITIS; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; EAR INFECTION; FATIGUE; HUMAN; HYPERTENSION; LOWER RESPIRATORY TRACT INFECTION; MACULOPAPULAR RASH; MALAISE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHUMAN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; REVIEW; RHINOPHARYNGITIS; SEPSIS; SINUSITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; GIANT LYMPH NODE HYPERPLASIA; MULTIPLE MYELOMA; PRECLINICAL STUDY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 84929406720     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-015-0453-1     Document Type: Review

References (49)

1. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619–26. doi:10.1038/ncprheum0338.
2. Bower M, Stebbing J. Exploiting interleukin 6 in multicentric Castleman’s disease. Lancet Oncol. 2014;15(9):910–2. doi:10.1016/S1470-2045(14)70333-X.
3. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res: Off J Am Assoc Cancer Res. 2003;9(13):4653–65.
4. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9(4):822–30.
5. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670–83.
6. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406–12.
7. Liu YC, Stone K, van Rhee F. Siltuximab for multicentric Castleman disease. Expert Rev Hematol. 2014;7(5):545–57. doi:10.1586/17474086.2014.946402.
8. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978;69(1):86–90.
9. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16(4):236–46. doi:10.1097/PAP.0b013e3181a9d4d3.
10. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989;74(4):1360–7.
11. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice. J Clin Invest. 1990;86(2):592–9. doi:10.1172/JCI114749.
12. Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood. 1998;91(6):1858–63.
13. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, et al. Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93(12):4034–43.
14. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677–84. doi:10.1097/SLA.0b013e318249dcdc.
15. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128(8):657–62.
16. Peterson BA, Frizzera G. Multicentric Castleman’s disease. Semin Oncol. 1993;20(6):636–47.
17. Fajgenbaum DC LA, Ruth J, et al. HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review Blood. 2014;4861 [Abstract]. Systematic review of 189 cases of idiopathic MCD which describes demographic, clinical, and laboratory features of iMCD as well as the treatments currently used in practice. This is the most comprehensive data on a subpopulation of a rare disease.
18. Muzes G, Sipos F, Csomor J, Sreter L. Multicentric Castleman’s disease: a challenging diagnosis. Pathol Oncol Res: POR. 2013;19(3):345–51. doi:10.1007/s12253-013-9619-z.
19. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25–35.
20. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103(5):1632–4. doi:10.1182/blood-2003-05-1721.
21. El-Osta HE, Kurzrock R. Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4):497–511. doi:10.1634/theoncologist.2010-0212.
22. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hemat Oncol: H&O. 2010;8(7):486–98.
23. Dham A, Peterson BA. Castleman disease. Curr Opin Hematol. 2007;14(4):354–9. doi:10.1097/MOH.0b013e328186ffab.
24. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129(1):3–17. doi:10.1111/j.1365-2141.2004.05311.x.
25. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991;78(5):1198–204.
26. van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol. 1998;102(3):783–90.
27. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood. 1995;86(8):3123–31.
28. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5. doi:10.1056/NEJM199403033300904.
29. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95(1):56–61.
30. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32. doi:10.1182/blood-2004-12-4602.
31. Nishimoto N HO, Sumikawa H, et al. A long-term (5-year) sustained efficacy of tocilizumab for multicentric Castleman’s disease and the effect on pulmonary complications. Blood. 2007;110.
32. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(23):3701–8. doi:10.1200/JCO.2009.27.2377.
33. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol: Off J AmSoc Clin Oncol. 1999;17(4):1244.
34. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Research: Off J Am Assoc Cancer Res. 2013;19(13):3659–70. doi:10.1158/1078-0432.CCR-12-3349. First prospective open- label phase 1 dose finding study of siltuximab used in Castleman’s disease. Initial data on clinical benefit response, safety, pharmacokinetics, and pharmacodynamics are described and a maximum tolerated dose for future studies is determined.
35. Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103(8):1154–62. doi:10.1038/sj.bjc.6605872.
36. Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, et al. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Investig New Drugs. 2013;31(3):669–76. doi:10.1007/s10637-012-9857-z.
37. van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–74. doi:10.1016/S1470-2045(14)70319-5. First prospective phase 2 study of siltuximab in idiopathic multicentric Castleman’s disease where efficacy over best supportive care is shown and tolerable safety data in this population is described.
38. Markham A, Patel T. Siltuximab: first global approval. Drugs. 2014;74(10):1147–52. doi:10.1007/s40265-014-0249-x.
39. Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X et al. An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease. vol 21. 2013.
40. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;161(3):357–66. doi:10.1111/bjh.12266.
41. San-Miguel J, Blade J, Shpilberg O, Grosicki S, Maloisel F, Min CK, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014;123(26):4136–42. doi:10.1182/blood-2013-12-546374. Large prospective cohort of newly diagnosed MM patients not eligible for transplant are not shown to have meaningful benefit from the addition of siltuximab.
42. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015;90(1):42–9. doi:10.1002/ajh.23868. Large cohort of relapsed/refractory myeloma patients did not see a benefit with the addition of siltuximab to bortezomib.
43. Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16(5):1652–61. doi:10.1158/1078-0432.CCR-09-2581.
44. Sylvant. SylvantTM (siltuximab) for injection [package insert]. Janssen Biotech, Inc; Horsham, PA, USA: 2014.
45. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Reports. 2002;4(3):250–5.
46. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80(3):733–7.
47. Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, et al. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol. 2014;73(1):35–42. doi:10.1007/s00280-013-2314-7.
48. Kirk M KR, van Rhee F, et al. Siltuximab Reverses Muscle Wasting In Patients With Multicentric Castleman’s Disease. Blood. 2013;122(21).
49. van Rhee F CC, Vernon MK, et al. Superior Restoration of Health with Siltuximab Among Multicentric Castleman’s Disease Patients When Measured By SF-36 Blood [Abstract]. 2014;4469. Analysis of randomized controlled trial which describes a trend to improve health and overall symptoms based on the SF-36 in MCD patients treated with siltuximab.